
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Adrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
Adrian Wiestner, MD, PhD, senior investigator, National Institutes of Health, discusses curing or managing patients with chronic lymphocytic leukemia (CLL).
<<<
